Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bromocriptine Mesylate

FDA-approved product (capsule, oral), marketed as Bromocriptine Mesylate, Cycloset, Parlodel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bromocriptine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Adenoma
  • Hyperprolactinemia
  • Hypogonadism
  • Infertility
  • Parkinson disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bromocriptine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bromocriptine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

    NCT02929485 · start 2013-07

    Registered record
    Registry ID
    NCT02929485
    Conditions
    Addiction
    Interventions
    Tolcapone; Placebo; Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2013-07
    Completion
    2018-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAddiction
    InterventionTolcapone; Placebo; Bromocriptine
    PhasePhase 4
    Registry statusWithdrawn

  • Vaginal Bromocriptine for Treatment of Adenomyosis

    NCT01821001 · start 2013-03

    Registered record
    Registry ID
    NCT01821001
    Conditions
    Adenomyosis
    Interventions
    Vaginal Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-03
    Completion
    2018-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis
    InterventionVaginal Bromocriptine
    PhasePhase 1
    Registry statusCompleted

  • Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

    NCT01673724 · start 2012-02

    Registered record
    Registry ID
    NCT01673724
    Conditions
    Parkinson's Disease
    Interventions
    pramipexole; Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-05-23
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Interventionpramipexole; Bromocriptine
    PhasePhase 4
    Registry statusCompleted

  • QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

    NCT01474018 · start 2011-11

    Registered record
    Registry ID
    NCT01474018
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    QR-bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2012-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionQR-bromocriptine
    PhasePhase 4
    Registry statusCompleted

  • Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy

    NCT00998556 · start 2010-06

    Registered record
    Registry ID
    NCT00998556
    Conditions
    Peripartum Cardiomyopathy
    Interventions
    Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2016-08
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripartum Cardiomyopathy
    InterventionBromocriptine
    PhasePhase 2
    Registry statusCompleted

  • A Model to Identify Specific Predictors of Spatial Neglect Recovery

    NCT00990353 · start 2009-01

    Registered record
    Registry ID
    NCT00990353
    Conditions
    Spatial Neglect; Hemispatial Neglect; Hemineglect; Unilateral Neglect; Visual Spatial Neglect; Sensory Neglect
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-01
    Completion
    2021-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpatial Neglect; Hemispatial Neglect; Hemineglect; Unilateral Neglect +2 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

    NCT01893450 · start 2008-06

    Registered record
    Registry ID
    NCT01893450
    Conditions
    Graves Ophthalmopathy
    Interventions
    Methimazole; Bromocriptine; Pentoxifylline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-06
    Completion
    2013-06
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraves Ophthalmopathy
    InterventionMethimazole; Bromocriptine; Pentoxifylline
    PhaseNot applicable
    Registry statusTerminated

  • MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

    NCT00605683 · start 2007-11

    Registered record
    Registry ID
    NCT00605683
    Conditions
    Idiopathic Parkinson's Disease
    Interventions
    Safinamide (as add-on therapy); Safinamide (as add-on therapy); Safinamide (as add-on therapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-11
    Completion
    2012-03
    Enrolment
    679

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinson's Disease
    InterventionSafinamide (as add-on therapy); Safinamide (as add-on therapy); Safinamide (as add-on therapy)
    PhasePhase 3
    Registry statusCompleted

  • Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets

    NCT00650520 · start 2007-05

    Registered record
    Registry ID
    NCT00650520
    Conditions
    Healthy
    Interventions
    BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg; Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-05
    Completion
    2007-07
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg; Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    PhasePhase 1
    Registry statusCompleted

  • Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg

    NCT00649168 · start 2007-04

    Registered record
    Registry ID
    NCT00649168
    Conditions
    Healthy
    Interventions
    BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg; Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-04
    Completion
    2007-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg; Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    PhasePhase 1
    Registry statusCompleted

  • The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism

    NCT00451672 · start 2007-01

    Registered record
    Registry ID
    NCT00451672
    Conditions
    Hyperaldosteronism; Hypertension
    Interventions
    bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-01
    Completion
    2007-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperaldosteronism; Hypertension
    Interventionbromocriptine
    PhasePhase 4
    Registry statusUnknown

  • Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine

    NCT00315081 · start 2006-05

    Registered record
    Registry ID
    NCT00315081
    Conditions
    Schizophrenia; Hyperprolactinemia
    Interventions
    Bromocriptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-05
    Completion
    2008-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Hyperprolactinemia
    InterventionBromocriptin
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin

    NCT00441363 · start 2005-02

    Registered record
    Registry ID
    NCT00441363
    Conditions
    Type 2 Diabetes
    Interventions
    Bromocriptine Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-02
    Completion
    2006-03
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionBromocriptine Mesylate
    PhasePhase 3
    Registry statusTerminated

  • Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism

    NCT00704860 · start 2005-02

    Registered record
    Registry ID
    NCT00704860
    Conditions
    Major Depression
    Interventions
    Open label pharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2010-12
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionOpen label pharmacotherapy
    PhasePhase 4
    Registry statusCompleted

  • Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

    NCT00377676 · start 2004-07

    Registered record
    Registry ID
    NCT00377676
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Cycloset; Usual Diabetes Therapy plus placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2007-01
    Enrolment
    3,095

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionCycloset; Usual Diabetes Therapy plus placebo
    PhasePhase 3
    Registry statusCompleted